Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Kalorama Reports | Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.

Several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis. In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:

* Melonoma Vaccines

* Lung Cancer Vaccines

* Prostate Cancer Vaccines

* Cervical Cancer Vaccines

* Brain Cancer Vaccines

* Colon/Rectal Cancer Vaccines

* Breast Cancer Vaccines

* Lymphoma Vaccines

* Ovarian Cancer Vaccines

* Leukemia Vaccines

* Bladder Cancer Vaccines

As part of its exhaustive research and analysis, this report provides:

* Forecasts for Future Revenues from Cancer Vaccines

* Cancer Epidemiology

* Reviews of Products in the Pipeline

* Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market

* Directory of Related Companies

Some of the issues discussed in this report important for anyone operating in this market include:

* Introduction

* Early Detection and Screening

* Monoclonal Antibodies and Therapeutic Vaccines

* Political and Social Pressure

* Insurance and Reimbursement Issues

* Personalized Medicine

* Pharmacogenomics

* Vaccine Strategies

* New Genetic Technique

* Future Growth in Vaccines

As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:

* Antigenics, Inc.

* Avax Technologies, Inc.

* Biovest International, Inc.

* Cell Genesys, Inc.

* Dendreon Corporation

* Genitope Corporation

* GlaxoSmithKline plc

* Merck & Company, Inc.

* Northwest Biotherapeutics, Inc.

* NovaRx

* Oncothyreon

* Vaccinogen

* Vical, Inc.

Nov 1, 2008

250 Pages - Pub ID: KLI1646591
Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions